异环磷酰胺单药治疗晚期肾癌后的中枢神经系统副作用。
Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.
作者信息
Heim M E, Fiene R, Schick E, Wolpert E, Queisser W
出版信息
J Cancer Res Clin Oncol. 1981;100(1):113-6. doi: 10.1007/BF00405909.
Abstract
Ten patients with advanced renal carcinoma were treated by ifosfamide (50-60 mg/kd/day x 5 days). The treatment was repeated every 4 weeks and continued until progression appeared. Two patients came into partial remission, two had subjective improvement, and six did not respond. Seven patients developed acute psychopathological symptoms during the first ifosfamide-cycle. Five patients had visual and paranoid hallucinations, four patients were completely confused. Follow-up for up to 10 weeks showed a persisting organic brain syndrome in five patients.
摘要
10例晚期肾癌患者接受了异环磷酰胺治疗（50 - 60毫克/千克/天，共5天）。每4周重复一次治疗，持续至病情进展。2例患者出现部分缓解，2例有主观改善，6例无反应。7例患者在第一个异环磷酰胺治疗周期出现急性精神病理症状。5例患者有视觉和妄想性幻觉，4例患者完全意识混乱。长达10周的随访显示5例患者存在持续性器质性脑综合征。
相似文献
1
Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.异环磷酰胺单药治疗晚期肾癌后的中枢神经系统副作用。
J Cancer Res Clin Oncol. 1981;100(1):113-6. doi: 10.1007/BF00405909.
2
Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.儿童癌症潜在肾毒性治疗后的早期和晚期肾脏不良反应。
Cochrane Database Syst Rev. 2013 Oct 8(10):CD008944. doi: 10.1002/14651858.CD008944.pub2.
3
Ifosfamide treatment as a 10-day continuous intravenous infusion.异环磷酰胺采用为期10天的持续静脉输注治疗。
J Cancer Res Clin Oncol. 1995;121(5):297-302. doi: 10.1007/BF01209597.
4
Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients.区域热疗联合全身化疗（异环磷酰胺加依托泊苷）改善晚期肉瘤局部控制：65例患者的最新报告
J Cancer Res Clin Oncol. 1991;117 Suppl 4:S141-7. doi: 10.1007/BF01613220.
5
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.对无法手术的胰腺癌患者连续5天输注异环磷酰胺并联合美司钠：一项II期研究。
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S135-8. doi: 10.1007/BF01613218.
7
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.在晚期难治性恶性肿瘤中，高剂量异环磷酰胺与骨髓生长因子联合进行6天持续输注。
J Cancer Res Clin Oncol. 1997;123(4):227-31. doi: 10.1007/BF01240320.
8
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.赞布替尼联合化疗作为HER2阳性晚期胃食管腺癌患者的一线治疗：一项多中心、单臂、2期研究的主要结果
Lancet Oncol. 2025 May 30. doi: 10.1016/S1470-2045(25)00287-6.
9
Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.顺铂/依托泊苷/异环磷酰胺逐步剂量递增联合粒细胞/巨噬细胞集落刺激因子治疗晚期睾丸癌患者。
J Cancer Res Clin Oncol. 1991;117 Suppl 4:S198-202. doi: 10.1007/BF01613227.
10
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.替沃扎尼联合纳武利尤单抗对比替沃扎尼单药治疗免疫检查点抑制剂治疗后的肾细胞癌患者：III 期 TiNivo-2 研究结果。
Lancet. 2024 Oct 5;404(10460):1309-1320. doi: 10.1016/S0140-6736(24)01758-6. Epub 2024 Sep 13.
引用本文的文献
1
Risk Factors for Ifosfamide-Related Encephalopathy in Adult Cancer Patients: An Integrative Review.成年癌症患者中异环磷酰胺相关脑病的危险因素：一项综合综述。
J Adv Pract Oncol. 2020 May-Jun;11(4):368-380. doi: 10.6004/jadpro.2020.11.4.4. Epub 2020 May 1.
2
Ifosfamide-Induced Metabolic Encephalopathy in 2 Patients With Cutaneous T-Cell Lymphoma Successfully Treated With Methylene Blue.2例皮肤T细胞淋巴瘤患者发生异环磷酰胺诱导的代谢性脑病，经亚甲蓝成功治疗。
J Investig Med High Impact Case Rep. 2018 Jul 6;6:2324709618786769. doi: 10.1177/2324709618786769. eCollection 2018 Jan-Dec.
3
Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.大剂量异环磷酰胺所致脑病：一项回顾性队列研究及文献综述
Drug Saf. 2008;31(11):989-96. doi: 10.2165/00002018-200831110-00003.
4
A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.
Cancer Chemother Pharmacol. 1986;18(3):280-3. doi: 10.1007/BF00273403.
5
Nephrotoxicity associated with ifosfamide.
Eur J Pediatr. 1988 Nov;148(2):164-6. doi: 10.1007/BF00445929.
6
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.毒性及对大剂量异环磷酰胺+美司钠作为晚期乳腺癌挽救治疗的反应
J Cancer Res Clin Oncol. 1988;114(6):602-4. doi: 10.1007/BF00398184.
7
Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.
Cancer Chemother Pharmacol. 1989;24 Suppl 1:S2-6; discussion S7. doi: 10.1007/BF00253227.
8
Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
Cancer Chemother Pharmacol. 1991;28(6):455-60. doi: 10.1007/BF00685822.
9
Common emergencies in cancer medicine: cardiovascular and neurologic syndromes.肿瘤医学中的常见急症：心血管和神经综合征
J Natl Med Assoc. 1991 Nov;83(11):1001-17.
本文引用的文献
1
Proceedings: Chemotherapy of adenocarcinoma of the kidney.会议论文：肾腺癌的化疗
Cancer. 1973 Nov;32(5):1062-5. doi: 10.1002/1097-0142(197311)32:5<1062::aid-cncr2820320506>3.0.co;2-u.
2
Clinical pharmacology of isophosphamide.
Clin Pharmacol Ther. 1974 Jul;16(1):77-86. doi: 10.1002/cpt1974161part177.
3
Pharmacokinetics of ifosfamide.异环磷酰胺的药代动力学。
Clin Pharmacol Ther. 1975 Apr;17(4):492-8. doi: 10.1002/cpt1975174492.
4
[Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].
Med Welt. 1975 May 16;26(20):972-9.
5
[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
Med Klin. 1978 Sep 8;73(36):1247-52.
6
[Clinical experience with the cytostatic drug ifosfamide].
Med Welt. 1977 Sep 2;28(35):1395-1400.
Zotero 插件